Compare Abbott Laboratories (ABT) vs ACM Research Inc (ACMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs ACM Research Inc — how do they compare? Abbott Laboratories trades at $111.17 (market cap $191.92B), while ACM Research Inc trades at $81.08 (market cap $5.66B). The key difference: Abbott Laboratories is far larger — about 33.9× ACM Research Inc's market cap, and Abbott Laboratories pays a 2.27% dividend while ACM Research Inc pays none. Which is the better fit depends on your goals.
| ABT | ACMR | |
|---|---|---|
Market Cap | $191.92B | $5.66B |
Sector | Health | Technology |
52-Week High | $136.62 | $126.89 |
52-Week Low | $82.57 | $25.02 |
Enterprise Value | $218.92B | $4.57B |
Dividend Yield | 2.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $111.27, up 1.39% on the day, with strong analyst support (76% buy ratings) and a consensus price target of $120.70. The stock shows bullish technical momentum with recent earnings beats in Q1 and Q2 2026, though Q4 2025 missed expectations. Revenue growth remains steady at $44.33B for 2025, with solid profitability metrics including 56.61% gross margin and 11.65% net income margin. Recent corporate developments include CE Mark approval for innovative dual glucose-ketone sensors and positive ACS guideline updates for Cologuard cancer screening.
The outlook remains positive with Wall Street consensus favoring accumulation, though risks include potential earnings volatility and competitive pressures in medical technology. The current valuation at 35.89 P/E appears reasonable given the company's innovation pipeline and market leadership. Upside potential exists toward the $120-134 analyst target range, supported by strong cash flow generation and dividend stability.
ACMR trades at $81.26, up 1.68% today, with a bullish technical signal and support near $81. Recent Q2 2026 earnings beat estimates with EPS of $0.61 versus $0.42 expected, and revenue grew 36% year-over-year to $292.9 million. The company raised its 2026 revenue guidance amid strong order growth of 105% in the first half, driven by new products and overseas expansion.
Outlook is positive with an 80% analyst buy rating and a consensus price target of $127.50, implying significant upside. Risks include high valuation multiples like a P/E of 38.33 and dependence on semiconductor cycle stability, but robust earnings momentum and institutional interest support growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About ACM Research Inc
ACM Research develops and manufactures semiconductor process equipment, specializing in wafer cleaning and electroplating solutions. Its tools are used by global chipmakers to improve productivity and yield for logic and memory chips.
Read more on ACMR →
